HAE
$49.43
Haemonetics
($.58)
(1.16%)
Earnings Details
1st Quarter June 2025
Thursday, August 7, 2025 6:00:00 AM
Tweet Share Watch
Summary

Haemonetics (HAE) Recent Earnings

Haemonetics (HAE) reported 1st Quarter June 2025 earnings of $1.10 per share on revenue of $321.4 million. The consensus earnings estimate was $1.01 per share on revenue of $303.3 million. Revenue fell 4.4% compared to the same quarter a year ago.

Haemonetics Corp is a healthcare company that provides blood management solutions to its customers. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals.

Results
Reported Earnings
$1.10
Earnings Whisper
-
Consensus Estimate
$1.01
Reported Revenue
$321.4 Mil
Revenue Estimate
$303.3 Mil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

Financial release accessible online

BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information:

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.

Direct link to 1Q FY26 Earnings Release:
https://haemonetics.gcs-web.com/static-files/078498e0-b75c-4cd4-94fb-93730b3b1c70

A replay of the conference call and webcast will be available for one year beginning on August 7, 2025, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:

Olga Guyette, Vice President-Investor Relations & Treasury 

David Trenk, Manager-Investor Relations

(781) 356-9763

(203) 733-4987

olga.guyette@haemonetics.com

david.trenk@haemonetics.com



Media Contact:

Josh Gitelson, Sr. Director-Global Communications

(781) 356-9776

josh.gitelson@haemonetics.com


Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-1st-quarter-fiscal-year-2026-earnings-release-available-on-investor-relations-website-302523396.html

SOURCE Haemonetics Corporation